Claim extract · Listening Library
Sames / Giant’s Shoulders: oxa-iboga alkaloids
LAST REVIEWED 2026-09-22 · RESEARCHER INTERVIEW · RELATED PRIMARY DOI
Landmark extract from Giant’s Shoulders #139 with Columbia chemist Dalibor Sames. Episode talk is media; pair it to the 2024 Nature Communications oxa-iboga alkaloid paper. Guest clinic mentions, if any, are context only — IbogaBase does not refer clinics.
Listening Library source (outbound)
Entry: giants-shoulders-139-dalibor-sames-2026 — YouTube watch?v=K9whp_wtCoc (2026-07-20). Catalog confidence: high; related primary already attached in LL JSON.
Institutional context (not scraped): Columbia Chemistry faculty listing for Dalibor Sames (Cloudflare-gated from some bots) — institutional page only, not a clinical claim.
Testable claims extracted (media → primary)
- Claim (paper title / abstract framing): Oxa-iboga alkaloids “lack cardiac risk” relative to ibogaine in the assays reported, and disrupt opioid use in animal models.
Primary: Havel, Kruegel, … Sames et al., “Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models,” Nature Communications 2024;15:8118. PMID 39304653, DOI 10.1038/s41467-024-51856-y. Published online 2024-09-20 (Crossref). - Claim (media extension risk): That animal cardiac-assay results mean human ibogaine or oxa-analogs are “safe” or clinically ready.
Verdict: Not established. Animal / in-vitro cardiac risk reduction ≠ human approval, dosing guidance, or Schedule I status change. Keep QTc and noribogaine / analogs desks separate. - Claim (taxonomy): Oxa-iboga species are interchangeable with plant iboga or clinical ibogaine hydrochloride.
Verdict: False for literacy purposes — see Compare.
Verdict
Strong preclinical / chemistry signal; not a human efficacy or safety approval. Use the interview to locate the paper; do not upgrade podcast enthusiasm into “best drug” or miracle language (IbogaBase refuses best-in-field claims).